Medtronic (MDT)
88.24
+1.10 (1.26%)
NYSE · Last Trade: Mar 16th, 5:21 PM EDT
Detailed Quote
| Previous Close | 87.14 |
|---|---|
| Open | 87.41 |
| Bid | 88.00 |
| Ask | 88.93 |
| Day's Range | 87.25 - 88.75 |
| 52 Week Range | 79.55 - 106.33 |
| Volume | 8,109,631 |
| Market Cap | 118.59B |
| PE Ratio (TTM) | 24.58 |
| EPS (TTM) | 3.6 |
| Dividend & Yield | 2.840 (3.22%) |
| 1 Month Average Volume | 8,918,214 |
Chart
About Medtronic (MDT)
Medtronic is a global leader in medical technology, focused on developing and providing innovative therapeutic solutions to improve the lives of patients. The company specializes in a wide range of medical devices and therapies, addressing conditions in areas such as diabetes care, cardiovascular health, surgical innovations, and neurological disorders. Medtronic is committed to advancing healthcare through cutting-edge research, collaboration with healthcare providers, and a strong emphasis on patient-centered care, aiming to enhance the quality of life for millions around the world. Read More
News & Press Releases
WASHINGTON D.C. — In a series of high-stakes maneuvers that have redefined the role of the U.S. Treasury, Secretary Scott Bessent has signaled a fundamental shift in American economic policy. As of March 16, 2026, the architect of the administration’s "Parallel Prosperity" agenda is simultaneously navigating a volatile
Via MarketMinute · March 16, 2026
As of March 16, 2026, the medical technology landscape is grappling with a stark reminder of the vulnerabilities inherent in the digital shift of healthcare. Stryker Corporation (NYSE: SYK), a global titan in medical devices and equipment, finds itself at the center of a developing storm following a massive cyberattack that has sent ripples through [...]
Via Finterra · March 16, 2026
Medtronic PLC (NYSE:MDT): A Dependable Dividend Stock with Strong Fundamentalschartmill.com
Via Chartmill · March 16, 2026

HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.
Via The Motley Fool · March 15, 2026
NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today reported its full year 2025 financial results and provided a fourth quarter business update.
By Orchestra BioMed Holdings, Inc. · Via GlobeNewswire · March 12, 2026
Shares of West Pharmaceutical Services (NYSE: WST) tumbled 5.7% on Tuesday following the announcement that Eric Green, the company’s President, Chief Executive Officer, and Chair of the Board, intends to retire. The decline, which wiped out significant market capitalization in a single session, reflects investor anxiety over the
Via MarketMinute · March 11, 2026
On a day marked by deepening global uncertainty and a sharp spike in energy costs, the healthcare sector emerged as the primary beneficiary of a massive "risk-off" migration by institutional investors. As of the market close on March 10, 2026, the Healthcare Select Sector SPDR Fund (NYSEARCA:XLV) gained 1%
Via MarketMinute · March 10, 2026
They are down, but they are not out.
Via The Motley Fool · March 10, 2026
Via Benzinga · March 10, 2026
Medtronic announces a $550 million Scientia Vascular acquisition to strengthen its neurovascular portfolio.
Via Benzinga · March 10, 2026
As the first quarter of 2026 draws to a close, the healthcare and life sciences sectors are grappling with a "new normal" defined by capital conservatism and geopolitical friction. Industry bellwethers, once buoyed by post-pandemic expansion and aggressive R&D spending, are now issuing sober forecast revisions that reflect a
Via MarketMinute · March 9, 2026
Edwards Lifesciences has outperformed the S&P 500 recently, and analysts remain moderately optimistic about the stock’s prospects.
Via Barchart.com · March 9, 2026
This Dividend King is out of favor, and this medical device peer has just introduced an exciting new product.
Via The Motley Fool · March 8, 2026
These stocks can be slow-and-steady wealth compounders.
Via The Motley Fool · March 5, 2026
MiniMed, a spinoff of Medtronic, is expected to price its IPO on March 5.
Via Barchart.com · March 3, 2026
Intuitive Surgical is the example to keep in mind as you watch this sleeper stock and its new surgical robot.
Via The Motley Fool · March 1, 2026
The established medical device titan is expanding into a promising new direction -- robotic surgery.
Via The Motley Fool · February 28, 2026
The best long-term winners often start small.
Via Barchart.com · February 26, 2026

One of the biggest growth stories in medical devices is Intuitive Surgical, but don't overlook the opportunity ahead for this competitor.
Via The Motley Fool · February 26, 2026
Medtronic has underperformed the S&P 500 over the past year. However, Wall Street analysts remain moderately optimistic about its prospects.
Via Barchart.com · February 26, 2026
Date: February 24, 2026 By: Financial Research Analyst Introduction For years, Medtronic plc (NYSE: MDT) was viewed by Wall Street as a reliable but sluggish giant—a "Dividend Aristocrat" that offered safety but lacked the high-octane growth of its specialized med-tech peers. That narrative is shifting rapidly. Today, February 24, 2026, marks a watershed moment for [...]
Via Finterra · February 24, 2026
In a definitive sign that the medical technology sector has moved past its post-pandemic stagnation, Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for the third fiscal quarter of 2026. On February 17, 2026, the Dublin-based medical device giant announced total revenue of $9.017 billion,
Via MarketMinute · February 23, 2026
The stock is especially attractive to income seekers.
Via The Motley Fool · February 22, 2026
The company operates in a field where spending often isn't optional.
Via The Motley Fool · February 22, 2026
The only healthcare stock I own is Medtronic, and I'm not planning to sell it anytime soon.
Via The Motley Fool · February 21, 2026